Dick P.  Allen 
Mr. Allen has served as independent lead director since March 2019 and on our board of directors since July 2007. He previously served as the Company's Chairman from August 2007 to January 2013 and from January 2016 to February 2019. Mr. Allen is engaged directly in the diabetes community through his personal involvement with JDRF and the Mary & Dick Allen Diabetes Center at Hoag Memorial Hospital Presbyterian. Mr. Allen served as a member of the International Board of Directors of JDRF from July 2008 to June 2014 and as Chairman from July 2012 to June 2014. He currently serves on the board of Providence St. Joseph Health where he chairs the finance committee. Mr. Allen has more than 50 years of experience in the health care industry and was previously the President of DIMA Ventures, Inc., a private investment firm providing seed capital and board-level support for start-up companies in the healthcare field. He was a co-founder and Vice President of Caremark, Inc., a home infusion therapy company that was later acquired by Baxter International. He was also a co-founder and director of Pyxis Corporation that was later acquired by Cardinal Health, Inc. Mr. Allen received a B.S. (cum laude) from Yale University and an M.B.A. from Stanford University Graduate School of Business where he served on the faculty as a Lecturer in Strategic Management for thirteen years.

Kim D. Blickenstaff
Mr. Blickenstaff has served as our Executive Chairman since March 2019 and as one of our directors since September 2007. He previously served as our President and Chief Executive Officer from September 2007 to February 2019. Prior to joining our company, Mr. Blickenstaff served as Chairman and Chief Executive Officer of Biosite Incorporated, or Biosite, a provider of medical diagnostic products, from 1988 until its acquisition by Inverness Medical Innovations, Inc. in June 2007. Mr. Blickenstaff previously served as a director of Medivation, Inc. (NASDAQ: MDVN), a biotechnology company, from 2005 to 2016, until its acquisition by Pfizer, and as a director of DexCom, Inc. (NASDAQ: DXCM), a provider of continuous glucose monitoring systems, from June 2001 to September 2007. Mr. Blickenstaff was formerly a certified public accountant and has more than 20 years of experience overseeing the preparation of financial statements. He received a B.A. in Political Science from Loyola University, Chicago, and an M.B.A. from the Graduate School of Business, Loyola University, Chicago.

Edward L. Cahill
Mr. Cahill has served on our board of directors since May 2009. Mr. Cahill has served as Managing Partner of HLM Venture Partners, a venture capital firm that invests primarily in emerging companies focused on healthcare information technology, healthcare services and medical technology, since May 2000. He served as a director of Animas Corporation, a developer of external insulin pumps, from March 2001 until its acquisition by Johnson & Johnson in February 2006. From June 1995 to May 2000, Mr. Cahill served as a founding partner of Cahill, Warnock Company (now Camden Partners), a venture capital firm based in Baltimore. Previously, Mr. Cahill was a Managing Director of Alex Brown & Sons, an investment services brokerage, where he led the firm’s healthcare group from January 1986 through March 1995. From January 1999 until August 2014, Mr. Cahill was a director of Masimo Corporation (NASDAQ: MASI), a medical technology company. He is also a director of several privately held healthcare companies and serves as a trustee of Johns Hopkins Medicine, Johns Hopkins Health System and Mercy Health Services. Mr. Cahill holds an A.B. in American Civilization from Williams College and a Masters of Public and Private Management from Yale University.

Howard E. Greene, Jr.
Mr. Greene has served on our board of directors since January 2008. Mr. Greene is an entrepreneur who has participated in the founding and management of 11 medical technology companies over 25 years, including three companies for which he served as chief executive officer. He was the co-founder of Amylin Pharmaceuticals, Inc., a public pharmaceutical company that was acquired by Bristol Myers Squibb in August 2012, serving as the Chief Executive Officer of that company from 1987 to 1996. He also served as a director of Amylin Pharmaceuticals from 1987 to April 2009. Mr. Greene also served on the board of directors of Biosite from June 1989 until its sale in 2007. From 1986 until 1993, Mr. Greene was a founding general partner of Biovest Partners, a seed venture capital firm. He was Chief Executive Officer of Hybritech Incorporated from March 1979 until its acquisition by Eli Lilly & Co. in March 1986, and he was co-inventor of Hybritech’s patented monoclonal antibody assay technology. Prior to joining Hybritech, he was an executive with the medical diagnostics division of Baxter Healthcare Corporation and a consultant with McKinsey & Company. Mr. Greene holds a B.A. in Physics from Amherst College and an M.B.A. from Harvard Business School.

Rebecca Robertson
Ms. Robertson has served on our board of directors since January 2019. Ms. Robertson is a founder and has served as Managing Director of Versant Ventures, where she specializes in medical devices and diagnostics, since November 1999. In addition, through Longridge Business Advisors, she has provided business advisory and board services since April 2017. Ms. Robertson served as a general partner at Institutional Venture Partners (IVP), where she was an investor in the life sciences group, from July 1997 to October 1999. Prior to that, Ms. Robertson served as senior vice president at Chiron Diagnostics, a division of Chiron Corporation, where she had responsibility for the critical care business unit in addition to leading the division’s business development efforts. Ms. Robertson was also previously an entrepreneur in residence for IVP in the life sciences group, a co-founder and Vice President at Egis, a consumer products company, and held senior management positions in operations and finance at Lifescan, a Johnson & Johnson Company. Ms. Robertson holds a B.S. in chemical engineering from Cornell University.

Douglas A. Roeder
Mr. Roeder has served on our board of directors since May 2009. Mr. Roeder joined Delphi Ventures as an Associate in 1998, and has been a Partner since 2000, focusing on medical devices, diagnostics and biotechnology. Prior to joining Delphi Ventures, Mr. Roeder was an Associate with Alex Brown’s Healthcare Investment Banking Group in San Francisco, where he focused on the medical device, life sciences and healthcare services industries. Mr. Roeder serves as a director of Senseonics Holdings, Inc. (NYSE-MKT:SENS), a continuous glucose monitoring company, and several privately held companies. He previously served as a director of Trivascular Technologies, Inc., a medical device company, which was acquired by Endologix, Inc. (NASDAQ: ELGX) in February 2016. He also previously worked with Putnam Associates, a strategy consulting firm focused on the pharmaceutical and biotechnology industries. Mr. Roeder holds an A.B. in Biochemistry from Dartmouth College.

Christopher J. Twomey
Mr. Twomey has served on our board of directors since July 2013. From March 1990 until his retirement in 2007, Mr. Twomey held various positions with Biosite, most recently serving as Senior Vice President, Finance and Chief Financial Officer. From 1981 to 1990, Mr. Twomey worked for Ernst & Young LLP, where he served as an Audit Manager. Mr. Twomey has also served as a director of Senomyx, Inc. (NASDAQ: SNMX), a flavor technology company, since March 2006 and is chair of that company’s audit committee. Mr. Twomey also served as a director and chair of the audit committee of Cadence Pharmaceuticals, Inc., from July 2006 until it was acquired by Mallinckrodt plc in March 2014. Mr. Twomey holds a B.A. in Business Economics from the University of California, Santa Barbara.

Richard P. Valencia
Mr. Valencia has served on our board of directors since June 2018. Mr. Valencia has served as President of Qualcomm Life, Inc., a subsidiary of Qualcomm Incorporated, since its formation in December 2011. Qualcomm Life focuses on commercial healthcare activities and offers products and services to enable wireless connectivity of medical devices and healthcare networks. As President of Qualcomm Life, Mr. Valencia has also overseen Qualcomm’s healthcare venture funds, dRx Capital and Qualcomm Life Fund. Prior to joining Qualcomm Life, Mr. Valencia served as Vice President and General Manager of Qualcomm Wireless Health beginning in October 2010. Earlier in his career, Mr. Valencia founded ProfitLine, Inc., a telecommunications expense management service provider, and served as Chief Executive Officer from 1992 until the sale of the company in 2009. Mr. Valencia received a Bachelor of Science in Finance from California State University, Northridge.

David Berger
Executive Vice President and Chief Legal & Compliance Officer
David Berger was appointed Executive Vice President and Chief Legal & Compliance Officer in April 2019 and is responsible for the Company’s legal, quality and regulatory functions.  He previously served as Executive Vice President and General Counsel and has overseen the legal department since August 2013. Prior to joining the company, he served as Senior Vice President, General Counsel and Corporate Secretary at Senomyx, Inc., which he joined in 2008. His prior experience includes serving as Vice President, Legal Affairs at Biosite Incorporated, where he was the managing attorney responsible for all commercial aspects of legal affairs, and serving as an attorney with Cooley Godward LLP. Mr. Berger received his J.D. at Stanford Law School and a B.A. in Economics from the University of California, Berkeley.

Kim Blickenstaff
Executive Chairman
Kim D. Blickenstaff has served as our Executive Chairman since March 2019 and as one of our directors since September 2007. He previously served as our President and Chief Executive Officer from September 2007 to February 2019. Prior to joining our company, Mr. Blickenstaff served as Chairman and Chief Executive Officer of Biosite Incorporated, a provider of medical diagnostic products, from 1988 until its acquisition by Inverness Medical Innovations, Inc. in June 2007. Mr. Blickenstaff currently serves as Chairman of Medivation, Inc. (NASDAQ: MDVN), and is a member of its audit committee and compensation committee. He previously served as a director of DexCom, Inc. (NASDAQ: DXCM), a provider of glucose monitoring systems, from June 2001 to September 2007. Mr. Blickenstaff was formerly a certified public accountant and has more than 20 years of experience overseeing the preparation of financial statements. He received a B.A. in Political Science from Loyola University, Chicago, and an M.B.A. from the Graduate School of Business, Loyola University, Chicago. 

Michael Fechko
VP, Manufacturing Operations
Michael Fechko was appointed VP of Manufacturing Operations in September 2019 with more than 20 years of experience in manufacturing and engineering in the medical device and semiconductor industries. He previously served as Senior Director of Manufacturing, following serving in successive roles in operations at Tandem since 2011. Prior to joining Tandem, Mr. Fechko was the Senior Manager of Manufacturing Engineering and Facilities at Volcano Corporation. He began his career at NEC Electronics. Mr. Fechko holds a B.S. in Mechanical Engineering from California State University, Chico.

Tom Fox
Vice President, Human Resources
Tom Fox was appointed Vice President, Human Resources in August 2017. He previously served as Senior Director of our Human Resources Department. Mr. Fox has more than 20 years of experience in Human Resources management.  Prior to joining Tandem, Mr. Fox served as Director of Human Resources for the Oncology-Genoptix Division of Novartis Pharmaceuticals.  Before that, he held various HR leadership positions including Director of Human Resources for the West Division of BDO, USA LLP; Director of HR Client Services for Option One Mortgage Company (a subsidiary of H&R Block Corp.) and Director of Labor and Employee Relations at The Walt Disney Company, Disneyland Resort. Mr. Fox began his career at Chevron Corporation and holds a B.S. in Business Administration from California State University, Fresno and a M.S. in Labor Relations and Human Resources Management from Michigan State University.

Brian Hansen
Executive Vice President and Chief Commercial Officer
Brian Hansen joined us as our Executive Vice President & Chief Commercial Officer in February 2016 with more than 20 years of sales and leadership experience in the clinical diagnostics industry. Prior to joining Tandem, Mr. Hansen was Chief Commercial Officer at Adaptive Biotechnologies Corporation. Before that, he held executive and senior-level positions at Genoptix (a Novartis-owned company), Gen-Probe (acquired by Hologic in 2012) and Fischer Scientific. Mr. Hansen received an MBA from the School of Business at San Diego State University and a B.S. in Business Administration from the University of Missouri – Columbia. 

Manuel Jaime
Senior Vice President, Technology and Digital Health
Manuel Jaime joined us as our Senior Vice President, Technology and Digital Health in February 2019 with more than 20 years of experience in incubating and commercializing emerging products and services in the high-tech industry. Prior to joining Tandem, Mr. Jaime was Chief Technology Officer at Cedar Electronics. Before that, he was a co-founder and Chief Executive Officer of ClipCast Technologies, and he previously held various roles at CardioNet and Qualcomm. He also is an inventor on more than 20 patents relating to connected devices, wireless systems, video platforms, and low-power radio frequency. Mr. Jaime is a graduate of the Leaders for Global Operations (LGO) Program at the Massachusetts Institute of Technology (MIT) Sloan School of Management where he received an MBA and a MS in Mechanical Engineering. He also holds a BS in Mechanical Engineering and a MS in Systems Engineering from MIT.

Julia Kensick
Vice President, Quality
Julia Kensick was appointed Vice President, Quality in August 2017. She previously served as Senior Director of Quality and has overseen the department since September of 2013. Ms. Kensick has more than 25 years of experience in quality, regulatory and customer affairs.  Prior to joining Tandem, Ms. Kensick served as Director of Quality for the Infusion Business Unit of CareFusion. Before that, she held positions including Executive Director of Regulatory and Customer Affairs for Ophthonix and Quality Assurance Director at American Medical Systems (Formerly CryoGen Inc.). Ms. Kensick began her career in the Vascular Intervention Group at Guidant and holds a Bachelor of Science in Mechanical Engineering from San Diego State University. 

Arun Kumar
Vice President, Supply Chain
Arun Kumar joined us as Vice President, Supply Chain in August 2019. He has broad executive experience in supply chain, service, and customer operations at companies such as Dexcom, Amazon, Dell, and FedEx. In his most recent roles at Dexcom and Stella & Dot he had global responsibility for warehousing, logistics, and distribution. From 2003 to 2009, he was Executive Director of Global Operations, Logistics, and Fulfillment at Dell, Inc. In his role as Managing Director at FedEx, from 1995 to 2000, he had responsibility for the Indian subcontinent in Mumbai, India, as well as for National Hub Operations, in Memphis, Tennessee. Mr. Kumar holds a master's degree in mechanical engineering from Old Dominion University.

Jim Leal
Senior Vice President, Operations
Jim Leal has served as our Senior Vice President, Operations since August, 2017. Mr. Leal joined Tandem in October 2010 as Vice President, Operations bringing 25 years of manufacturing and engineering experience. Previously, Mr. Leal was the Vice President of Manufacturing and Field Support for Volcano Corporation and held Director Roles with CardioNet, Inc. and Digirad Corporation. He held Senior Engineering roles with FlipChip Technologies and Hughes Aircraft Company. Jim has won several awards including a Hughes Aircraft Doctoral and Masters Fellowship and was a recognized nominee for Most Promising Hispanic Engineer of the Year Award. Mr. Leal is a published author and patent holder. He is a University of Arizona graduate with a Ph.D. in Materials Science and Engineering.

Michael Michaud
VP, Research and Development
Michael Michaud was appointed VP of Research and Development in September 2019 with more than 10 years of engineering experience in the medical device industry. He previously served as Senior Director of Research and Development, following serving in successive R&D roles at Tandem since 2009. Prior to joining the Company, Mr. Michaud was a research and development engineer for Trimedyne, Inc. and before that was product development engineer for Applied Medical. Mr. Michaud holds a B.S. in Mechanical Engineering from the University of Michigan.

Susan Morrison
Executive Vice President and Chief Administrative Officer
Susan Morrison was appointed Chief Administrative Officer in September 2013. She previously served as our Vice President, Human Resources, Corporate and Investor Relations since April 2013. Ms. Morrison served as our Director, Corporate and Investor Relations, from January 2009 to March 2013, and was our Director, Corporate Services from November 2007 to December 2008. Prior to joining our company, Ms. Morrison held various positions in Corporate and Investor Relations at Biosite from August 2003 through November 2007. Ms. Morrison holds a B.A. in Public Relations from Western Michigan University.

Dave Nuttall
Vice President, Finance
Dave Nuttall joined us in July 2019 as our Vice President of Finance, bringing with him over 30 years of medical device business experience. Prior to Tandem, Dave spent 13 years with Philips Healthcare as the Head of Finance, Therapeutic Care Division. Previously, Mr. Nuttall held finance-related executive roles in the Respiratory Care Division of Medtronic. In his 18 years with the company, he also led M&A activities and worked in operations. Mr. Nuttall holds a bachelor’s degree in accounting from Fort Lewis College.

Jeff Risher
Vice President and General Counsel
Jeff Risher was appointed Vice President and General Counsel in August 2019. He brings with him 20 years of legal, intellectual property, and business strategy experience, including over 15 years in-house at technology, manufacturing, and medical device companies. Before joining Tandem, Mr. Risher was Vice President, Technology & Intellectual Property at electric vehicle developer Faraday Future, and prior to this he held the role of Deputy General Counsel at Tesla. Mr. Risher spent nine years at Apple, where he served as Director of Patent Strategy and Licensing, as well as Director of Patent Litigation. He has held in-house legal roles at Abbott Laboratories, where he was responsible for patent litigation and counseling relating to glucose monitoring and insulin pump technologies, and at Entefy, Inc., an artificial intelligence start-up. Mr. Risher began his career as a litigator at Latham & Watkins LLP and Rutan & Tucker LLP in Orange County, California. Mr. Risher received his J.D. from UCLA Law School, and his B.A. in Philosophy (combined with the pre-medical sciences curriculum) from Dartmouth College.

John Sheridan
President and Chief Executive Officer
John F. Sheridan has served as our President and Chief Executive Officer since March 2019. He previously served as our Executive Vice President and Chief Operating Officer since April 2013. Prior to joining our company, Mr. Sheridan served as Chief Operating Officer of Rapiscan Systems, Inc., a provider of security equipment and systems, from March 2012 to February 2013. Mr. Sheridan served as Executive Vice President of Research and Development and Operations for Volcano Corporation (NASDAQ: VOLC), a medical technology company, from November 2004 to March 2010. From May 2002 to May 2004, Mr. Sheridan served as Executive Vice President of Operations at CardioNet, Inc., a medical technology company. From March 1998 to May 2002, he served as Vice President of Operations at Digirad Corporation, a medical imaging company. Mr. Sheridan holds a B.S. in Chemistry from the University of West Florida and an M.B.A. from Boston University.

Ross Sylvia
Vice President, Marketing
Ross Sylvia joined us as our Vice President, Marketing and Product Management in April 2019, bringing with him more than 15 years of experience as an executive in the medical device, health sciences, and biotechnology industries. Prior to joining Tandem, Mr. Sylvia was Global Vice President, Thoracolumbar Fixation and Pediatrics at San Diego-based NuVasive, a medical device company focused on developing innovative surgical products and solutions for spine surgery. Mr. Sylvia has held a variety of leadership positions in product management, market development, marketing, and sales at NuVasive, K2M, Inc., and Johnson & Johnson. Mr. Sylvia holds a B.S. in marketing and computer information systems from Bryant University.

Leigh Vosseller
Executive Vice President and Chief Financial Officer
Leigh Vosseller was appointed Executive Vice President and Chief Financial Officer effective January 1, 2018. Previously, Ms. Vosseller served as our Senior Vice President, Finance from August 2017. Ms. Vosseller joined Tandem in August 2013 as Vice President, Finance. Prior to joining Tandem, Ms Vosseller served in various senior finance positions in the healthcare industry. Most recently, she was Vice President and CFO of Genoptix, Inc. (a Novartis company). Prior to that she held a senior finance position at Biosite Incorporated where she played a key role in developing the financial and administrative infrastructure for international expansion. Ms. Vosseller is a certified public accountant (inactive) and holds a bachelor’s degree in accounting from Missouri State University.